KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Free Cash Flow: 2010-2024

Historic Free Cash Flow for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $171.2 million.

  • Supernus Pharmaceuticals' Free Cash Flow fell 215.89% to -$61.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.8 million, marking a year-over-year decrease of 58.87%. This contributed to the annual value of $171.2 million for FY2024, which is 54.91% up from last year.
  • According to the latest figures from FY2024, Supernus Pharmaceuticals' Free Cash Flow is $171.2 million, which was up 54.91% from $110.5 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Free Cash Flow registered a high of $171.2 million during FY2024, and its lowest value of $110.5 million during FY2023.
  • Its 3-year average for Free Cash Flow is $132.7 million, with a median of $116.4 million in 2022.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Free Cash Flow fell by 8.43% in 2022 and then skyrocketed by 54.91% in 2024.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Free Cash Flow stood at $134.9 million in 2020, then dropped by 5.80% to $127.1 million in 2021, then decreased by 8.43% to $116.4 million in 2022, then fell by 5.05% to $110.5 million in 2023, then soared by 54.91% to $171.2 million in 2024.